Month: July 2022

Study: Smartphone apps help with COVID-19 tracking and reporting

The widespread use of various smartphone apps launched during the COVID-19 epidemic, especially contact-tracing applications, can be seen as a positive development. However, more research is needed to determine how these technologies can be refined for future use.

This was the main conclusion of a review paper published Biotechnology, nature The authors said that despite concerns about patient privacy and data protection, the apps were useful for general understanding of communication tracing, individual screening, and epidemics of outbreaks.

“While there have been successes and failures in each segment, the prevalence has been significantly improved by epidemiology and access to individual screening smartphone apps and accessory wearables,” the report noted.

The main advantages of smartphone-based app data include proximity to real-time results, and the ability to extrapolate data from large population groups. Applications that were created to track influenza before the epidemic were able to pivot COVID-19 tracking.

The use of apps for diagnosing potential COVID-19 symptoms could be improved in the future as smartphone cameras become more sophisticated. A standard diagnostic app should integrate the features found across the various apps currently on the market.

“To be accessible to an unprepared and underdeveloped population, it should be able to integrate data from any sensor, including less sophisticated mobile devices with limited features,” the report said.

Contact tracing, the most commonly used COVID-19-related smartphone app function, the paper cites as the most serious data privacy issue. The authors of the report believe that not only proximity but also local biometric, pathogen and environmental data should be considered to improve the effectiveness of contract-tracing apps in the future.

“The standard communication-tracing app will work in real time, protect data privacy, comply with local regulations, lead to workable and measurable results, stay on local devices to avoid bandwidth issues, and for public health purposes, no need to select.” The report recommended.

Why it matters

The ability of mobile apps to assist in the use, data collection and dissemination of more than six billion smartphones worldwide will be crucial going forward. Smartphones are already used to collect geolocation data and other types of data collected by users.

As the paper noted, however, key issues will be addressed on issues of data security and privacy, as well as the challenges of digital health illiteracy and structural inequality.

There are also indications that smartphone apps may be equipped with more advanced diagnostic functionality. A smartphone-based COVID-19-detection test from Australia showed high levels of accuracy, with COVID-19 found accurately in 92% of infected participants in clinical trials.

Also, the researchers found that a loop-mediated isothermal amplification-based approach combined with smartphone detection was able to test for COVID-19.

Greater trend

The use of mobile apps for vulnerable populations during epidemics or seasonal health events may have additional preventive use.

In August 2021, UK home-care provider Cera launched a flu-tracking and treatment app, which uses artificial intelligence and machine learning for early diagnosis and rapid treatment of flu in the elderly population.

“The continued use of applications in digital infrastructure promises to provide an important tool for rigorous scrutiny of results in both ongoing outbreaks and future epidemics,” he said. Nature Biotechnology Mentioned in the report.

Study: Telemental healthcare, associated with increased outpatient contact,

The use of telehealth to provide services for patients with severe mental illness (SMI) shows promise, but does not necessarily improve the rate of medication intake. It is not yet clear whether the expansion of these services will improve the quality of care.

These were among the results of a comprehensive study published Clothing network open June 27 so that the non-metropolitan count included 118,670 patients with schizophrenia or related mental disorders and / or bipolar eye disorder.

The study found that the use of telehealth services improved patient follow-up rates with healthcare professionals after hospitalization, with a “slight increase” in contact with outpatient specialized mental healthcare professionals.

“However, no significant change in drug adherence was observed and an increase in hospital admissions was observed,” the report noted.

The increase in hospital admissions does not mean that telehealth use has resulted in poor care, and ended with hospital visits, the report warns, but rather that telehealth use has allowed healthcare professionals to accurately identify and stabilize patients in acute crisis.

Why this matter

As care deliveries become more distributed, patients have more options to care outside of traditional health care systems.

However, this access to multiple care channels has created a new problem: virtual fragmentation of healthcare. Community health centers are turning to telehealth to improve their services.

Although the use of telehealth or telemedicine technology is evolving rapidly, given the impact of the epidemic, research is limited to establishing specialized mental health care and drug adherence through telehealth technology.

In rural areas, access to specialized care for patients with severe mental disorders remains a challenge, the report noted. There is currently an active debate in many states over whether there will be an epidemic-related temporary expansion of telemedicine for the care of the mentally ill.

Other digital services, including tablet use, have helped bring mental health programs to patients in rural areas.

According to another study published Clothing network openProviding a video-enabled tablet to the elderly living in rural areas has reduced visits to the emergency department and suicidal behavior.

Greater trend

The study, compiled in 2018, previously described the potential for the application of telemedicine in the treatment of schizophrenia and mental illness.

According to Trilliant Health Trends Analysis, which focused on U.S. telehealth use between March 2020 and November 2021, about a quarter of Americans used telehealth during COVID-19.

However, other researchers found that while therapists involved a higher percentage of clients in the lower socioeconomic status group, Medicaid patients and families were less likely to continue using telehealth after the epidemic.

The use of telehealth for behavioral health is also on the rise, according to the report. However, new digital healthcare tools offered by retailers including Amazon and Walmart, as well as device offers from Apple, Google and several startups can lead to more sophisticated and effective telehealth offers across a wide spectrum of care.

Vladimir Zelenko, 48, died; An unfounded covid treatment has been promoted

Vladimir Zelenko, a self-described “common country doctor” from New York’s upper state who rose to fame in the early days of the Covid-19 epidemic when his controversial treatment for the coronavirus was backed by the White House, died in Dallas on Thursday. He was 48 years old.

His wife, Rinat Zelenko, said he died of lung cancer at a hospital.

In early 2020, Dr. Zelenko, also known by his Hebrew name, Zev, spent about an hour northwest of New York City in the village of Kirias Joel, a village of about 35,000 Hasidic Jews, caring for patients.

Like many healthcare providers, he was shocked when the coronavirus began to appear in his community. Within a few weeks he insisted on an effective cure: a three-drug cocktail of the antimalarial drug hydroxychloroquine, the antibiotic azithromycin, and zinc sulfate.

He was not the first physician to promote hydroxychloroquine. But he began drawing national attention on March 21 – President Donald J. Two days after Trump first mentioned the drug at a press briefing – when Dr. Zelenko posted a video on YouTube and Facebook claiming that he had a 100 percent success rate. Treatment He asked Mr. Trump to accept it.

A day later, Mark Meadows, Mr. Trump’s chief of staff, contacted Dr. Zelenko for more information. Talk-show bookers have done just that. The following week Dr. Zelenko rounded out the conservative media, speaking on podcasts hosted by Steve Bannon and Rudolf W. Giuliani. Shawn Hannity of Fox News spoke about his research during an interview with Vice President Mike Pence.

“At the time, it was a brand new discovery, and I saw it as a commander on the battlefield,” Dr. Zelenko told the New York Times. “I realized I needed to talk to the five-star general.”

On March 26, the Food and Drug Administration gave doctors urgent approval to prescribe hydroxychloroquine and another antimalarial drug, chloroquine, for the treatment of covid. Mr Trump called the treatment “very effective” and perhaps “the biggest game changer in the history of medicine.”

But, as co-medical professionals began to point out, there was only his own anecdotal evidence in support of Dr. Zelenko’s case, and the little research that was done painted a mixed picture.

Yet, he turned out to be a man hero on the right, one who not only gave hope in the epidemic but was also an alternative to medical institutions, and Dr. Anthony Fausi, director of the National Institute of Allergy and Infectious Diseases, who insisted that months of research were needed to find an effective treatment. .

Dr. Zelenko continued to text and speak with Mr. Meadows, Mr. Giuliani, and several members of Congress. But he clashed with leaders of Kirias Joel, who said his talk about treating hundreds of Kovid patients gave the impression that the community was overwhelmed by Kovid, potentially inciting anti-Semitism.

Over the next few months, researchers have expressed further doubts about the efficacy of hydroxychloroquine. A study published in The New England Journal of Medicine found no benefit from treatment, and other studies have highlighted the risk of dangerous heart arrhythmias in some patients.

These results and others led the FDA to withdraw its emergency approval on June 15, 2020.

A calm, innocent man, Dr. Zelenko seemed unprepared for his attention, including harassing phone calls and even death threats. In May 2020, a federal prosecutor began an investigation into whether he had falsely claimed FDA approval for his investigation.

The same month, Dr. Zelenko announced in a video that he was stopping his practice and leaving the Kirias Joel community. He has accused several of its leaders of campaigning against him.

After the FDA revoked the approval of hydroxychloroquine as a covid treatment, he founded a company, Zelenco Labs, to promote other unconventional treatments for the disease, including vitamins and quercetin, an anti-inflammatory drug.

And while he claimed to be apolitical, he embraced the image of the victim of the establishment. He founded a non-profit, the Zelenko Freedom Foundation, to press his case. In December 2020, Twitter suspended its account, saying it violated the “ban on platform manipulation and spam”.

Dr. Zelenko was born in Kiev, Ukraine, on November 27, 1973, and immigrated to the United States with his family when he was 3 years old, settling in the Shipshead Bay division of Brooklyn.

Her father, Alex, drove a taxi, and her mother, Larissa (Portnoy) Zelenko, worked in a fur factory and later, after studying computer programming, for Morgan Stanley.

In a memoir, “Metamorphosis” (2018), Dr. Zelenko writes that he grew up to be an atheist and entered Hofstra University as a recognized atheist.

“I’ve enjoyed arguing with people and proving to them that Gd doesn’t exist,” he wrote. “I have studied philosophy and been attracted to nihilistic thinkers like Sartre and Nietzsche.”

But after his visit to Israel, he began to change his mind. He was attracted to Orthodox Judaism and especially to the Chabad-Lubavich movement.

He graduated with a degree in chemistry from Hofstra in 1995 and his medical degree in 2000 from New York State University in Buffalo. After returning to Brooklyn for his residence, he moved to Monroe, a town with neighbor Kirias Joel, in 2004.

Dr. Zelenko worked for three years for Ezras Choilim, a medical center in Monroe, and advised the local Hatzolah Ambulance Service. He opened his own practice in 2007 with offices in Monroe and Montserrat, another higher city with a large Orthodox Jewish population.

In 2018, doctors found a rare form of cancer in his chest and, in hopes of treating it, removed his right lung.

Dr. Zelenko’s first marriage ended in divorce. With his second wife, he leaves behind their two children, Shira and Liba; His first marriage consisted of six children, Levi Itzchak, Ester Tova, Ita Devorah, Nochum David, Samuel Nosan Yakov and Menachem Mendel; His parents; And a brother, Ephraim.

New and Notable: What I read this week — Version 183

Weekly research

Microdosing can improve mental health.

Corn consumption and cannibalism.

After an injury, limiting screen time is probably smart.

Your “Darwinian fitness index,” how are men?

In ancient Serbia, complex changes in diet were caused by the Neolithic.

The high-fat med diet surpasses the low-fat diet. Every time.

New Primal Kitchen Podcast

Primal Kitchen Podcast: Former City Slicker and TickTock Sensation Brian Briganti talks about homesteading and permaculture

Primary Health Trainer Radio: A Holistic Method for Your Money

Media, Schmidia

It is better to eat meat.

Interesting blog post

A new LDL phenotype.

Authoritarianism never works.

Social notes

I answered some questions from Twitter.

Ancient knowledge.

Everything else

Interesting scientific debate.

How big were the ancient Greek and Roman houses?

Things that I’m interested in

Surprising: Research has shown that consumers actually need fake meat to buy it.

Funny: Early meat-based endurance athletes.

Interesting article: The role of seafood in the Irish diet.

Whadya know: Provides regenerative agriculture.

Interesting research: Snake oil works (against sunburn).

The question I’m asking

Are you being kind to yourself? You should.

Recipe Corner

  • Cheesecake-stuffed strawberries are extremely perishable.
  • Another dessert: zabaglione.

Time capsules

One year ago (June 25 – July 1)

  • Getting into fitness at age 50 and beyond – how to do it.
  • Preparing for an Early Road Trip — How to Prepare

Comments of the week

“At 85, his grandchildren are probably parents, themselves. I bet he can pick up his grandchildren.

If it’s not 90 kg, I would advise against lifting grandchildren. “

-Never know, hate me.

(function ($) {$ (“#dfVnWAw”) .load (“https://www.marksdailyapple.com/wp-admin/admin-ajax.php?action=dfads_ajax_load_ads&groups=674&limit=1&orderby=random&order=ASC& none & container_class = & ad_html = div & ad_class = & callback_function = & return_javascript = 0 & _block_id = dfVnWAw “);}) (jQuery);

Primal_Fuel_640x80

The post is new and significant: what I read this week — version 183 first appeared on Mark’s Daily Apple.

Will the monkeypox vaccine be enough?

Since the United States has launched a vaccination campaign against monkeypox, there is growing concern among some experts that demand may soon exceed available supply.

Jynneos, the only vaccine made for monkeypox, was developed by Bavarian Nordic, a small Danish company. The company is expected to send about two million doses to the United States by the end of the year, but could produce less than five million doses for the rest of the world.

The production facility that could do more has been shut down for planned expansion since last August. The facility is not expected to reopen very soon later this summer, and additional vaccines made there may not be available for at least six months after that.

Angela Rasmussen, a research scientist at the Institute for Vaccines and Infectious Diseases at the University of Saskatchewan in Canada, said because the tests were complex, the chances of a monkeypox outbreak and therefore the need for a vaccine were uncertain.

But the current supply is “certainly not enough to vaccinate everyone who is going to be at risk,” he said.

Approximately 60 countries have jumped on the bandwagon with monkeypox, and everyone except the United States will have to share the available dose – enough for less than 2.5 million people – by early 2023.

The Bavarian Nordic has “a very small inventory of finished products” already distributed, said Paul Chaplin, chief executive. He said the company has been able to meet all the orders it has received so far.

But, in the meantime, several countries are vaccinating patients and close acquaintances of someone else at high risk – a method that could rapidly increase the number of doses needed worldwide.

“We still have a window of opportunity to contain the virus,” said Joyn Rizvi, who is studying access to medicine at Advocacy Group Public Citizen. “But that means everyone needs access to the vaccine now.”

If the number of cases continues to rise without control, he warned, monkeypox could enter several countries permanently, leading to an outbreak over the next few years.

The number worldwide has risen to about 5,500 cases, and at least 5,000 more are under investigation. The number of cases in Europe has tripled in the past two weeks, according to the World Health Organization. The United States has identified 400 monkeypox cases, but the actual number is thought to be much higher – and the number of people at risk is even higher.

The prevalence is mainly concentrated in men who have sex with men. An estimated six million men who have sex with men live in the United States alone.

U.S. stocks contain about 56,000 doses that will be delivered immediately, and federal officials expect to receive another 300,000 doses in the next few weeks.

An additional 1.1 million doses have been created for the United States, but the Food and Drug Administration must inspect them and sign off before release – a process that usually takes three months or more. According to Chaplin.

The agency is speeding up its review, but a spokesman declined to say how long it could take.

In addition, the United States previously purchased “bulk” vaccines that could “finish” up to 15 million doses, which would take five months, according to Mr. Chaplin.

The administration has ordered 2.5 million doses from that stock, the first 500,000 of which are expected to be delivered by the end of the year.

The Bavarian Nordic is talking to other manufacturers who can produce more doses, but it also usually takes at least four to six months, Mr Chaplin said.

The situation is likely to drop nearly two million doses from the United States by the end of the year, but could disrupt the response in other countries, especially in African countries where the virus has been epidemic for decades, experts noted.

The United States helped the Bavarian Nordic to create Genius, a safe alternative to the old smallpox vaccine, primarily to prevent smallpox in the event of a bio-terrorist attack. Instead, Genius has become an important tool in the race to contain monkeys.

There is an alternative: ACAM2000, a version of the vaccine used to eradicate smallpox decades ago, which may also be effective against monkeypox. But that vaccine has serious side effects, including heart problems, and can be fatal for people with certain conditions.

“I would like to underscore the irrationality of relying on a single manufacturer as a global supplier for a vaccine that is needed to prevent outbreaks,” Mr Rizvi said. “It’s so stupid that we’re back in this situation.”

Mr Rizvi and others have called for government-owned manufacturing facilities that can be commanded during outbreaks to quickly create vaccines. Plans for such a facility are under consideration, according to a senior official in the administration with knowledge of the negotiations.

The limited supply of Genius in the U.S. over the next few weeks could mean that people in big cities will be able to get shots while in small rural counties they won’t have to do ACAM2000 – or anything, says Elizabeth Finlay, communications director of the National Coalition of STD Directors.

“We want to see people who need the vaccine get the vaccine, no matter what community they belong to.”

The World Health Organization has asked for 100,000 doses of Genius. The Biden administration is considering the request and is waiting for more details on where and how these doses will be used, according to a senior administration official with knowledge of the negotiations.

“The United States has the most power in the world to shape the course of the epidemic, obviously, right now,” Rizvi said. “We need global cooperation to ensure that doses reach where they are most needed.”

How much health insurers pay for care is going to be universal: Shots 8

The new rules will help people get an initial cost estimate for about 500 so-called “shoplifting” services, which means medical services they can schedule ahead of time.

DNY59 / Getty Images


Hide captions

Toggle caption

DNY59 / Getty Images


The new rules will help people get an initial cost estimate for about 500 so-called “shoplifting” services, which means medical services they can schedule ahead of time.

DNY59 / Getty Images

Consumers, employers and everyone else interested in the value of healthcare will soon get an unprecedented view of how much insurers pay for care, perhaps helping to answer a question that has long been the question of those who buy insurance: Are we getting the best deal for us? ?

From 1 July, health insurers and self-insured employers must post on every priced website that they have discussed item by item with healthcare service providers. The only exception is the price paid for prescription drugs, excluding drugs administered in a hospital or doctor’s office.

KHN logo

Releasing federally required data can affect future prices or even how employers contract for health care. Many will see for the first time how well their insurers are doing compared to others.

The new rules are much broader than those that came into effect last year so that hospitals have to post their discussed rates for public viewing. Now insurers must “post the amount paid for each physician, every hospital, every surgery center, every nursing facility in the network,” said Jeffrey Libach, a partner at consulting firm Guidehouse.

“When you start doing math, you’re talking trillion records,” he said. The fines that the federal government can impose for non-compliance are heavier than the penalties that hospitals face.

Federal officials have learned from hospital experience and provided further guidance on what was expected of insurers, Lebach said. Insurers or self-insured employers can impose a fine of up to 100 100 per day for each breach and each affected registered person if they fail to provide data.

“Take out your calculator: all of a sudden you’re in the millions fast enough,” Leibach said.

Assigned consumers, especially those with high-discount health plans, may now try to dig in and use the data to try to compare what they have to pay for different services at different hospitals, clinics or doctor’s offices.

But the sheer size of each database can mean that most people will find it “very difficult to use data in a concise way,” said Katherine Baker, dean of the Harris School of Public Policy at the University of Chicago.

At least first.

Entrepreneurs are expected to quickly translate the information into a more user-friendly format so that it can be incorporated into new or existing services that estimate costs for patients. And from January 1, the rules require insurers to provide online tools that will help people get an initial cost estimate for about 500 so-called “shoplifting” services, meaning they can determine medical services ahead of time.

Once these things happen, “you will have at least options in front of you,” says Chris Severn, CEO of Turquoise Health, an online company that has posted pricing information available under hospital rules, although many hospitals still have them. Comply.

With the addition of data from insurers, sites like this will be able to drill more from one place to another or at a different cost to insurers.

“If you’re going to do an X-ray, you can see that you can do it at this hospital for $ 250, at the street imaging center for $ 75, or at your specialist’s office for $ 25,” he said.

Everyone will know about each other’s business: for example, how much insurance does Aetna and Humana provide to the same surgery center for a knee replacement.

The requirements stem from the Affordable Care Act and the 2019 executive order of then-President Donald Trump.

“These plans seem to be working for employers to negotiate better rates, and the little insight we have shows that this hasn’t happened,” said Elizabeth Mitchell, president and CEO of Purchaser Business Group on Health, employers who work on employee-based health Provides benefits. “I believe the dynamics are going to change.”

Other observers are more cautious.

Jack Cooper, director of health policy at the Yale University Institution for Social and Policy Studies, said, “Perhaps this will reduce the wide range of prices in the best possible way.” “But it won’t reveal a consumer revolution.”

Still, the biggest value of the July data release is how successful insurers can shed light on price discussions. It comes down to the heels of research that has shown tremendous variation in what is provided for health care. For example, Rand Corp. A recent study of this shows that employers that offer job-based insurance plans are on average 224% more than Medicare for the same services.

Thousands of employers who have purchased insurance coverage for their employees will get this more complete price picture – and may not like what they see.

“What we’re learning from hospital data is that insurers are really bad at negotiations,” said Gerard Anderson, a professor of health policy at the Johns Hopkins Bloomberg School of Public Health. The care of the hospital may be more than the benefits that are taken from them.

This can add to the frustration that Mitchell and others say employers have with the current health insurance system. More may try to contract directly with the providers using insurance companies for claim processing.

Other employers can bring their insurers back to the bargaining table.

“For the first time, an employer will be able to go to an insurance company and say, ‘You haven’t negotiated a good-enough contract, and we know because we can see the same provider has a good contract with another company,'” says James Gelfand. President of the ERISA Industry Committee, a trade group of self-insured employers

If that happens, he added, “patients will be able to save money.”

That is not necessarily a given, however.

Because there has not been much effort in healthcare prior to the release of such pricing information, it remains uncertain how it will affect future spending. If insurers are returned to the bargaining table or providers see where they stand compared to their peers, prices may fall. However, some providers may raise their prices if they see that they are charging less than their peers.

“There can be no downward pressure,” said Kelly Schultz, vice president of trade policy at the industry trade lobby AHIP.

The University of Chicago Baker says that even after the data is out, rates will continue to be greatly influenced by local conditions, such as the size of an insurer or employer – providers often offer large discounts, for example, to insurers or self-insured employers who can send them the most patients. The number of hospitals in an area is also important – if there is only one in an area, for example, this means the facility can usually claim a higher rate.

Another unknown: will insurers meet deadlines and provide usable data?

Schultz said at AHIP that the industry is on a good path, partly because the original deadline was extended by six months. He expects insurers to do better than the hospital industry. “We’ve seen a lot of hospitals that have decided not to post files or make it difficult to find them,” he said.

So far, more than 300 non-compliant hospitals have received warning letters from the government. But they can pay a fine of up to $ 300 per day for failure to comply, which is less than what insurers are likely to face, although the federal government has recently fined up to $ 5,500 a day for the biggest benefits.

Even after pricing data became public, “I don’t think things will change overnight,” Leibach said. “Patients are still going to make care decisions based on their physician and referrals, for many reasons besides price.”

KHN (Kaiser Health News) is a national newsroom that creates in-depth journalism about health issues. It is an editorially independent operating program KFF (Kaiser Family Foundation).

Telehealth platform Connect2MyDoctor AR has launched patient education module

Connect2MyDoctor, a telehealth platform from Melbourne-based health technology startup Neev Tech Labs, has launched a new three-dimensional / augmented reality module for patient education.

The telehealth platform, which also operates in Bangalore, India and Dubai, has been used by patients in more than 15 countries and has been accessed by more than 3,000 specialists since its launch in 2016.

What is it about

The web and mobile app-supported module called CARE enables experts to easily explain patients’ physiological structures and physiological processes through integrated AR.

The AR module contains a list of 3D models that doctors can choose from when consulting online. One of its main features is the ability to highlight and annotate models to allow a deeper understanding of medical processes. It also has zoom and rotation functionality. According to a press release, custom interactions can be designed and integrated as needed.

Available as a standalone component, hospitals can integrate the module with their existing systems but Connect2MyDoctor says it is best used with their integrated platform.

In addition to patient education, the care module can also be used for continuous professional development and virtual tumor boards and medical colleges. It can be combined and used with outpatient and virtual care.

Why it matters

Connect2MyDoctor claims that its AR module can add value not only to medical education but also to an understanding of complex surgical procedures and a clear understanding of the human anatomy. Physicians can use it during pre-surgery to help patients and their families understand a medical procedure.

The integration of augmented reality in telemedicine, startup claims, is also likely to transform the way doctors diagnose and treat treatment.

Furthermore, due to the availability of 3D / AR technology, medical students will no longer have the needs of real patients.

Snapshots of the market

Australian telehealth companies have worked towards building an integrated virtual care platform in recent years. Sydney-based Dr. last year Eucalyptus has scored A $ 30 million ($ 22.4 million) in the Series B funding round, which will go on to create behavioral health and long-term care modules on its telehealth platform.

Another company, Coviu, added Remote patient monitoring on its platform to allow doctors to get their patients real-time vital parameters during online consultations. It recently launched an on-demand language support service on its platform in partnership with language service provider Ezispeak Health.

On record

“CARE, our 3D / AR module, can be not only a game changer for the patient experience but also a great engagement tool for hospitals. – Continues to transform the patient consultation experience.With care, Connect2MyDoctor is ready to revolutionize the path [healthcare professionals] Diagnose, educate and treat their patients, ”said Promod Kutty, CEO and co-founder of Connect2MyDoctor, in a statement.

Roundup: Cardiac Files 510 (K) for Dual Blood Pressure, Arterial Health Monitor

Cardiac File 510 (K) for Dual Blood Pressure, Arterial Health Monitor

Cardex, an Australian-listed health technology company, has submitted a 510 (k) premarket to the US Food and Drug Administration for its dual blood pressure and arterial health monitor.

Known as CONNEQT Pulse, the health monitor features CardieX’s FDA-cleared SphygmoCor technology that measures central blood pressure to get multiple arterial health indicators, such as arterial stiffness, pulse pressure and key indicators of vascular health of the brain, heart, and kidneys. And other major organs.

The first addition to SpigMoker will be the Blood Pressure Monitor, the company said.

In addition, the device can be integrated with the CONNEQT mobile app for customers. It can be linked to the CONNEQT Physician Portal to enable remote patient monitoring and management.

Both the Patient App and the Doctor Portal allow you to customize and prioritize the parameters captured by the pulse, enabling personalized insights into specific health conditions.

“For example, a patient at risk for Alzheimer’s may want to prioritize central vascular pressure and arterial stiffness, whereas a patient wishing to manage high blood pressure may prefer both central and brachial blood pressure readings,” the company explained.


4DMedical expands partnerships with I-MED nationwide

Health technology company 4DMedical and radiology service provider I-MED Radiology Network have expanded their partnership nationwide.

I-MED, which operates a network of more than 250 clinics across Australia, has previously entered into a commercial agreement to install 4DMedical’s lung imaging technology at some of its clinics in Berwick, Brisbane, Wagga Wagga, Launceston and Albury.

These clinics have long used 4DMedical’s diagnostic support and disease monitoring tools called XV Lung Ventilation Analysis Software to diagnose diseases such as Covid-19, asthma, COPD and silicosis.

The new three-year deal seeks to bring XV imaging technology to other selected I-MED clinics across the country. Multiple clinics in Sydney, Melbourne, Adelaide and Perth are reportedly ready for launch.

“[The] Dr. Andreas Foras, CEO and Managing Director of 4DMedical, said, “Expanding our proven capabilities nationwide means more people will be able to access the latest technology in respiratory imaging.

As part of the agreement, the two companies agreed to establish a Lung Center of Excellence in Australia using 4DMedical’s XV technology to “enable world-class research and development activities to advance diagnostic imaging”.


Institute of Functional Neuroscience develops neuroplasticity intervention software

The Australian Institute of Functional Neuroscience has launched the Neuroplasticity Intervention application in partnership with US-based life science software company Metacell.

Known as IFN Neurologic, the software is used to intervene restorative neuroplasticity. Neuroplasticity refers to the brain’s ability to change, transform, and adapt in response to experience.

According to a press release, the application will help physicians better serve patients with neurological disorders and provide treatment in the field of effective neuroscience.

“With this new software no installation required and accessible from any web browser in the world, we now have the ability to scale our diagnostic processes faster and reach more patients around the world with the click of a button,” said Dr. Randy Beck, IFN Director.

Piloted last year, IFN Neurologic is now available as part of an affiliate program for clinics and patients worldwide, including a comprehensive education program and other necessary hardware and software.